

11 April 2024

AstraZeneca increases 2024 dividend by 7%

AstraZeneca announced today that the Board intends to increase the annualised dividend for 2024 by \$0.20 to \$3.10 per share, underlining the company's confidence in its performance and cash generation. This takes into account other capital allocation priorities as well as previously announced acquisitions and business development.

Michel Demaré, Chair, AstraZeneca said: "The Board is delighted to announce a 7% increase to the dividend, taking it to \$3.10 per share. This uplift is in line with our progressive dividend policy, which remains unchanged, and reflects the continuing strength of AstraZeneca's investment proposition for shareholders."

No changes are planned to the Company's normal dividend payment timetable, which is:

- First interim dividend - announced with half-year results and paid in September.
- Second interim dividend - announced with full-year results and paid in March.

The Board also reaffirms its commitment to AstraZeneca's progressive dividend policy.

Notes

[AstraZeneca](#)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media [@AstraZeneca](#)

Contacts

For details on how to contact the Investor Relations Team, please click [here](#). For Media contacts, click [here](#).

Adrian Kemp
Company Secretary
AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DIVDZGMDLGVGDZM